Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04592913
Title Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin

Docetaxel + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.